Announcement
27.04.2011


At the company's Annual General Meeting today, the following issues were
adopted by the general meeting:

-- The 2010 Annual Report and the Board of Director's proposal regarding the
transfer of profits and losses for 2010 to next year were adopted.

-- The Board of Directors was re-elected and thus still consists of Thomas
Hofman-Bang (Chairman), Allan Andersen, Torbjörn Bjerke, Anders Ullman, Ian
Talmage, Lars Siim Madsen (elected by the employees), Torben Skov (elected
by the employees) and Mads Peder Gersdorff Korsgaard (elected by the
employees).

-- PricewaterhouseCoopers was re-elected as the company's auditor.

-- VP Investor Services A/S (CVR-nr. 30 20 11 83), Weidekampsgade 14, P.O. Box
4040, DK-2300 Copenhagen S, was appointed as the keeper of the company's
register of shareholders instead of Computershare A/S, Kongevejen 418,
DK-2840 Holte.

-- The Board's proposed remuneration policy for the Board of Directors and
Executive Management was adopted.

-- The fee to the Board of Directors for 2010 and 2011 was approved.

-- The general meeting authorised the Board to purchase own shares of up to a
total nominal value of DKK 49,107,894 (corresponding to 10% of the
company's present share capital) in the period until the next Annual
General Meeting.

Patrik Dahlen
CEO

Contact persons:
Patrik Dahlen, CEO, telephone: +45 2629 7296
René Schneider, EVP & CFO, telephone: +45 2911 2097

About NeuroSearch - Company profile
NeuroSearch A/S is a European based biopharmaceutical company, specialising in
CNS diseases, and listed on NASDAQ OMX Copenhagen A/S (NEUR). The company has a
pipeline of speciality CNS drugs, including Huntexil® (pridopidine), a unique
orphan drug in Phase III for the treatment of Huntington's disease. NeuroSearch
is building commercial competences with a view to commercialising Huntexil®
through an in-house marketing and sales organisation.

NeuroSearch has a well-established drug discovery division, NsDiscovery, with
unique capabilities in the field of ion channels and CNS diseases. The company
has strategic drug discovery and development alliances with Janssen
Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott.
NeuroSearch also has equity interests in a number of unlisted companies in the
Life Science industry.